Role of platelet-activating factor in primary hemostasis

M. Livio, G. Vigano, M. Morigi, A. Ubiali, M. Galbusera, G. Remuzzi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To determine whether platelet-activating factor (PAF) has a physiological role in the process of primary hemostasis in the rabbit, we measured skin bleeding times in animals given orally a specific PAF-receptor antagonist L-652,731. One hour after the administration of L-652,731 (20 or 40 mg/kg), a significant prolongation of bleeding time was observed. Parameters known to interfere with the process of primary hemostasis were not altered by PAF-receptor antagonist. In addition, no changes were observed in platelet count and vessel wall arachidonic acid metabolism, as revealed by serum thromboxane B2 levels, vascular 6-ketoprostaglandin F(1α) generation, and by aspirin experiment. The fact that aspirin alone did not induce prolongation of bleeding time in rabbits is probably due to the simultaneous inhibition of platelet thromboxane A2 and vascular prostacyclin. [3H]PAF binding to washed platelets of rabbits given L-652,731 showed a significant reduction in maximum number of detectable binding sites in comparison with values found in the same animals before the L-652,731 administration. The results suggest that the bleeding-time prolongation observed after L-652,731 administration results from its ability to selectively inhibit PAF bioactivity. Thus locally released PAF appears to exert a physiological role in the process of platelet plug formation that follows a skin incision in the rabbit.

Original languageEnglish
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume254
Issue number6
Publication statusPublished - 1988

Fingerprint

2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran
Platelet Activating Factor
Hemostasis
Bleeding Time
Rabbits
Blood Platelets
Aspirin
Blood Vessels
Thromboxane B2
Skin
Thromboxane A2
Epoprostenol
Platelet Count
Arachidonic Acid
Binding Sites
Serum

ASJC Scopus subject areas

  • Physiology

Cite this

Role of platelet-activating factor in primary hemostasis. / Livio, M.; Vigano, G.; Morigi, M.; Ubiali, A.; Galbusera, M.; Remuzzi, G.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 254, No. 6, 1988.

Research output: Contribution to journalArticle

@article{d8df8ee9748549a58f048325b44049dd,
title = "Role of platelet-activating factor in primary hemostasis",
abstract = "To determine whether platelet-activating factor (PAF) has a physiological role in the process of primary hemostasis in the rabbit, we measured skin bleeding times in animals given orally a specific PAF-receptor antagonist L-652,731. One hour after the administration of L-652,731 (20 or 40 mg/kg), a significant prolongation of bleeding time was observed. Parameters known to interfere with the process of primary hemostasis were not altered by PAF-receptor antagonist. In addition, no changes were observed in platelet count and vessel wall arachidonic acid metabolism, as revealed by serum thromboxane B2 levels, vascular 6-ketoprostaglandin F(1α) generation, and by aspirin experiment. The fact that aspirin alone did not induce prolongation of bleeding time in rabbits is probably due to the simultaneous inhibition of platelet thromboxane A2 and vascular prostacyclin. [3H]PAF binding to washed platelets of rabbits given L-652,731 showed a significant reduction in maximum number of detectable binding sites in comparison with values found in the same animals before the L-652,731 administration. The results suggest that the bleeding-time prolongation observed after L-652,731 administration results from its ability to selectively inhibit PAF bioactivity. Thus locally released PAF appears to exert a physiological role in the process of platelet plug formation that follows a skin incision in the rabbit.",
author = "M. Livio and G. Vigano and M. Morigi and A. Ubiali and M. Galbusera and G. Remuzzi",
year = "1988",
language = "English",
volume = "254",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - Role of platelet-activating factor in primary hemostasis

AU - Livio, M.

AU - Vigano, G.

AU - Morigi, M.

AU - Ubiali, A.

AU - Galbusera, M.

AU - Remuzzi, G.

PY - 1988

Y1 - 1988

N2 - To determine whether platelet-activating factor (PAF) has a physiological role in the process of primary hemostasis in the rabbit, we measured skin bleeding times in animals given orally a specific PAF-receptor antagonist L-652,731. One hour after the administration of L-652,731 (20 or 40 mg/kg), a significant prolongation of bleeding time was observed. Parameters known to interfere with the process of primary hemostasis were not altered by PAF-receptor antagonist. In addition, no changes were observed in platelet count and vessel wall arachidonic acid metabolism, as revealed by serum thromboxane B2 levels, vascular 6-ketoprostaglandin F(1α) generation, and by aspirin experiment. The fact that aspirin alone did not induce prolongation of bleeding time in rabbits is probably due to the simultaneous inhibition of platelet thromboxane A2 and vascular prostacyclin. [3H]PAF binding to washed platelets of rabbits given L-652,731 showed a significant reduction in maximum number of detectable binding sites in comparison with values found in the same animals before the L-652,731 administration. The results suggest that the bleeding-time prolongation observed after L-652,731 administration results from its ability to selectively inhibit PAF bioactivity. Thus locally released PAF appears to exert a physiological role in the process of platelet plug formation that follows a skin incision in the rabbit.

AB - To determine whether platelet-activating factor (PAF) has a physiological role in the process of primary hemostasis in the rabbit, we measured skin bleeding times in animals given orally a specific PAF-receptor antagonist L-652,731. One hour after the administration of L-652,731 (20 or 40 mg/kg), a significant prolongation of bleeding time was observed. Parameters known to interfere with the process of primary hemostasis were not altered by PAF-receptor antagonist. In addition, no changes were observed in platelet count and vessel wall arachidonic acid metabolism, as revealed by serum thromboxane B2 levels, vascular 6-ketoprostaglandin F(1α) generation, and by aspirin experiment. The fact that aspirin alone did not induce prolongation of bleeding time in rabbits is probably due to the simultaneous inhibition of platelet thromboxane A2 and vascular prostacyclin. [3H]PAF binding to washed platelets of rabbits given L-652,731 showed a significant reduction in maximum number of detectable binding sites in comparison with values found in the same animals before the L-652,731 administration. The results suggest that the bleeding-time prolongation observed after L-652,731 administration results from its ability to selectively inhibit PAF bioactivity. Thus locally released PAF appears to exert a physiological role in the process of platelet plug formation that follows a skin incision in the rabbit.

UR - http://www.scopus.com/inward/record.url?scp=0023935583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023935583&partnerID=8YFLogxK

M3 - Article

VL - 254

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 6

ER -